Residual basal cell carcinoma after treatment with imiquimod: A caution on assuming complete cure

Dermatologic Surgery

Volumn 33, Issue 12, 2007, Pages 1516-1519

  Harting, Mandy ^a   Vujevich, Justin ^b   Goldberg, Leonard H ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DERMSURGERY ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER SURGERY; CANCER THERAPY; CASE REPORT; CELL DIFFERENTIATION; DERMIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; NEOPLASM, RESIDUAL; SCALP; SKIN NEOPLASMS; TREATMENT FAILURE;

EID: 36749056892     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2007.33328.x     Document Type: Article

References (14)

1. Huber A, Huber J, Skinner RB Jr., et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 2004 30 : 429 30.
2. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999 41 : 1002 7.
3. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicentre 6-week dose-response trial. J Am Acad Dermatol 2001 44 : 807 13.
4. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002 138 : 1165 71.
5. Cowen E, Mercurio MG, Gaspari A. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol 2002 47 : S240 8.
6. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002 147 : 1227 36.
7. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004 50 : 722 3.
8. Sapijaszko MJA. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett 2005 10 : 2 5.
9. McCutcheon B, White K, Kotwall C, et al. A preliminary study of imiquimod treatment in variants of basal cell carcinoma. Am Surg 2005 71 : 662 5.
10. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005 31 : 318 23.
11. Dummer R, Urosevic M, Kempf W, et al. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003 149 Suppl 66 : 57 8.
12. Woodmansee C, Pillow J, Skinner RB Jr. The role of topical immune response modifiers in skin cancer. Drugs 2006 66 : 1657 64.
13. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006 45 : 489 98.
14. Li VW, Li WW, Talcott KE. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005 4 : 708 17.